MedTrace Logo

Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

NCT02283671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-02-27

No results posted yet for this study

Summary

First in human study to assess the tolerability and safety profile of treatment with dendritic cell in patients with multiple sclerosis or neuromyelitis optica.

Conditions

Interventions

BIOLOGICAL

Tolerogenic Dendritic cells loaded with myelin peptides

Somatic-cell therapy medicines application

Sponsors & Collaborators

  • Sara Varea

    lead OTHER

Principal Investigators

  • Pablo Villoslada, MD PhD · Institut d'Investigacions Biomèdiques August Pi i Sunyer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-07-10
Completion
2019-07-10

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283671 on ClinicalTrials.gov